Hedi Brahim - Transgene CEO Director
TRGNF Stock | USD 1.59 0.00 0.00% |
Insider
Hedi Brahim is CEO Director of Transgene SA
Age | 42 |
Phone | 33 3 88 27 91 00 |
Web | https://www.transgene.fr |
Transgene Management Efficiency
The company has return on total asset (ROA) of (0.1628) % which means that it has lost $0.1628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3623) %, meaning that it generated substantial loss on money invested by shareholders. Transgene's management efficiency ratios could be used to measure how well Transgene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Troy Weaver | Axalta Coating Systems | 52 | |
Tyrone Jordan | Axalta Coating Systems | 59 | |
Gregory Janey | Toro Co | 42 | |
Alisa Mall | JBG SMITH Properties | 43 | |
Joseph Pierce | Merit Medical Systems | N/A | |
Kevin Carpenter | Toro Co | 49 | |
John Knorpp | Merit Medical Systems | N/A | |
Stephen Webster | Luxfer Holdings PLC | 52 | |
Barbat Rodgers | JBG SMITH Properties | N/A | |
Andrew Wamser | Mativ Holdings | 50 | |
Gina Boswell | Acco Brands | 58 | |
Omar Hoek | Mativ Holdings | 55 | |
Sarma Malladi | Mativ Holdings | N/A | |
Jill Pemberton | Toro Co | 50 | |
Laura Murray | Hudson Pacific Properties | N/A | |
Michel Voigt | Merit Medical Systems | 51 | |
Nicole Priest | Merit Medical Systems | N/A | |
Missy Elam | Mativ Holdings | N/A | |
E Rajkowski | Acco Brands | 62 | |
George Xanders | JBG SMITH Properties | 38 | |
Michael Gaiden | Luxfer Holdings PLC | N/A |
Management Performance
Return On Equity | -0.36 | |||
Return On Asset | -0.16 |
Transgene SA Leadership Team
Elected by the shareholders, the Transgene's board of directors comprises two types of representatives: Transgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Transgene. The board's role is to monitor Transgene's management team and ensure that shareholders' interests are well served. Transgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Transgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
Maud MD, VP Officer | ||
Eric Quemeneur, Executive Vice President Vice President - Research & Development, Member of the Management Committee | ||
Gaelle Stadtler, VP HR | ||
JeanPhilippe Del, Vice President - Finance, Member of the Management Committee | ||
Elisabetta Castelli, Director of Investor Relations | ||
Hedi Brahim, CEO Director | ||
Lucie Larguier, Director IR | ||
Steven RPh, VP Officer | ||
LLM JD, Gen VP | ||
Philippe Slos, Head Laboratory |
Transgene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Transgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.36 | |||
Return On Asset | -0.16 | |||
Profit Margin | (1.27) % | |||
Operating Margin | (1.39) % | |||
Current Valuation | 152.15 M | |||
Shares Outstanding | 100.2 M | |||
Shares Owned By Institutions | 1.70 % | |||
Price To Earning | (7.42) X | |||
Price To Book | 0.02 X | |||
Price To Sales | 10.71 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Transgene Pink Sheet
Transgene financial ratios help investors to determine whether Transgene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.